Consolidated Financial Statements

June 30, 2024 (With comparative financial information as of and for the year ended June 30, 2023)

(With Independent Auditors' Report Thereon)

Independent Auditors' Report

The Board of Trustees
The Rockefeller University:

Opinion

We have audited the consolidated financial statements of The Rockefeller University and its subsidiary (the University), which comprise the consolidated balance sheet as of June 30, 2024, and the related consolidated statements of activities and cash flows for the year then ended, and the related notes to the consolidated financial statements.

In our opinion, the accompanying consolidated financial statements present fairly, in all material respects, the financial position of the University as of June 30, 2024, and the changes in its net assets and its cash flows for the year then ended in accordance with U.S. generally accepted accounting principles.

Basis for Opinion

We conducted our audit in accordance with auditing standards generally accepted in the United States of America (GAAS). Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We are required to be independent of the University and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibilities of Management for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with U.S. generally accepted accounting principles, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the University's ability to continue as a going concern for one year after the date that the consolidated financial statements are issued.

Auditors' Responsibilities for the Audit of the Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the consolidated financial statements.

In performing an audit in accordance with GAAS, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the consolidated financial statements, whether
 due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures
 include examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated
 financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are
 appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of
 the University's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting
 estimates made by management, as well as evaluate the overall presentation of the consolidated financial
 statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the University's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control related matters that we identified during the audit.

Report on Summarized Comparative Information

We have previously audited the University's 2023 consolidated financial statements, and we expressed an unmodified audit opinion on those audited consolidated financial statements in our report dated November 8, 2023. In our opinion, the summarized comparative information presented herein as of and for the year ended June 30, 2023, is consistent, in all material respects, with the audited consolidated financial statements from which it has been derived.

(signed) KPMG LLP

New York, New York Date

Consolidated Balance Sheet

June 30, 2024

(With comparative financial information as of June 30, 2023)

Assets	2024	2023
Cash and cash equivalents	\$ 66,956,928	31,142,442
Accounts receivable	19,259,218	13,939,291
Contributions receivable (note 9)	204,769,701	206,516,464
Loans receivable – faculty and staff	40,689,119	40,414,747
Other assets	32,663,877	30,978,612
Investments (note 3)	2,581,830,177	2,525,942,577
Plant assets, net (note 7)	1,076,321,722	1,104,253,063
Total assets	\$ 4,022,490,742	3,953,187,196
Liabilities and Net Assets		
Liabilities:		
Accounts payable and accrued expenses	\$ 55,632,564	47,727,547
Deferred revenues	23,552,159	29,188,570
Contingent liabilities (note 12)	48,207,934	26,625,464
Obligation under derivative instruments (note 6)	51,397,387	67,473,916
Obligation under lines of credit (note 5)	100,000,000	_
Long-term debt (note 6)	983,676,335	986,014,815
Conditional asset retirement obligation	9,731,616	9,173,915
Postretirement benefit obligation (note 8)	60,794,000	58,150,000
Amounts held for others (note 13)	151,594,988	151,017,718
Total liabilities	1,484,586,983	1,375,371,945
Commitments and contingencies (notes 3, 7, and 12)		
Net assets (notes 4 and 10):		
Without donor restrictions	64,506,755	169,292,642
With donor restrictions	2,473,397,004	2,408,522,609
Total net assets	2,537,903,759	2,577,815,251
Total liabilities and net assets	\$ 4,022,490,742	3,953,187,196

See accompanying notes to consolidated financial statements.

Consolidated Statement of Activities

Year ended June 30, 2024 (With summarized comparative financial information for the year ended June 30, 2023)

	2024			2023	
	Without donor		With donor		
	_	restrictions	restrictions	Total	Total
Revenues:					
Government grants and contracts	\$	110,367,775	_	110,367,775	101,522,703
Private gifts and grants		15,901,296	147,236,532	163,137,828	164,256,077
Investment income, net (note 3)		25,911,688	147,989,988	173,901,676	2,335,999
Net appreciation in fair value of derivative					
instruments (note 6)		16,076,529	_	16,076,529	27,374,167
Sales and services of auxiliary enterprises		34,195,323	_	34,195,323	31,944,257
Royalty and other income		26,170,221	_	26,170,221	20,639,236
Net assets released from restrictions (note 10)	_	224,823,446	(224,823,446)		
Total revenues	_	453,446,278	70,403,074	523,849,352	348,072,439
Expenses and other changes:					
Expenses (note 11):					
Research		305,300,377	_	305,300,377	274,782,549
Graduate education		21,531,366	_	21,531,366	19,183,852
Research support		46,346,056	_	46,346,056	46,174,255
Institutional support		61,261,511	_	61,261,511	60,517,043
Auxiliary enterprises	_	40,222,365		40,222,365	37,648,692
Total expenses		474,661,675	_	474,661,675	438,306,391
Other changes:					
Postretirement-related changes other than net					
periodic postretirement benefit cost (note 8)		(64,000)	_	(64,000)	(15,088,000)
Litigation payments (notes 11 and 12)		83,634,490	_	83,634,490	70,064,213
Provision for uncollectible contributions receivable	_		5,528,679	5,528,679	
Net expenses and other changes	_	558,232,165	5,528,679	563,760,844	493,282,604
Change in net assets		(104,785,887)	64,874,395	(39,911,492)	(145,210,165)
Net assets at beginning of year	_	169,292,642	2,408,522,609	2,577,815,251	2,723,025,416
Net assets at end of year	\$	64,506,755	2,473,397,004	2,537,903,759	2,577,815,251

See accompanying notes to consolidated financial statements.

Consolidated Statement of Cash Flows

Year ended June 30, 2024 (With comparative financial information for the year ended June 30, 2023)

		2024	2023
Cash flows from operating activities:			
Change in net assets	\$	(39,911,492)	(145,210,165)
Adjustments to reconcile change in net assets to net cash used in operating activities:	•	(**,***,**=/	(, , ,
Net appreciation in fair value of investments		(175,673,364)	(4,387,014)
Net appreciation in fair value of derivative instruments		(16,076,529)	(27,374,167)
Depreciation and amortization		54,509,200	55,223,644
Provision for uncollectible contributions receivable		5,528,679	_
Private gifts and grants restricted for long-term investment		(15,232,502)	(12,048,947)
Contributions for capital		(1,362,440)	(1,546,746)
Contingent liabilities		21,582,470	(45,439,643)
Changes in operating assets and liabilities:			
Accounts receivable		(5,319,927)	(48,564)
Contributions receivable, excluding amounts in financing activities		(8,660,253)	(18,612,490)
Other assets		(1,685,265)	(1,069,711)
Accounts payable and accrued expenses		8,500,342	(1,141,599)
Deferred revenues		(5,636,411)	(1,819,055)
Conditional asset retirement obligation		557,701	551,813
Postretirement benefit obligation		2,644,000	(11,928,000)
Amounts held for others		(10,382,777)	(8,493,935)
Net cash used in operating activities		(186,618,568)	(223,344,579)
Cash flows from investing activities:			
Proceeds from sale of investments		433,308,030	706,350,724
Purchase of investments		(324,841,202)	(582,194,498)
Additions to plant assets		(28,916,339)	(52,991,863)
Change in accounts payable for capital expenditures		(595,325)	(1,392,798)
Principal collections on loans receivable – faculty and staff		1,110,811	2,734,241
Issuance of loans – faculty and staff		(1,385,183)	(1,113,902)
Net cash provided by investing activities		78,680,792	71,391,904
Cash flows from financing activities:			
Proceeds from private gifts and grants restricted for long-term investment		14,273,279	28,194,902
Proceeds from private gifts restricted for capital		7,200,000	9,200,000
Proceeds from lines of credit		100,000,000	125,000,000
Repayment of lines of credit			(186,000,000)
Net cash provided by (used in) financing activities		121,473,279	(23,605,098)
Net increase (decrease) in cash, cash equivalents, and restricted cash		13,535,503	(175,557,773)
Cash, cash equivalents, and restricted cash at beginning of year (note 1 (c))		76,372,722	251,930,495
Cash, cash equivalents, and restricted cash at end of year (note 1 (c))	\$	89,908,225	76,372,722
Supplemental disclosures:			
Interest paid	\$	41,450,677	42,731,653
Net appreciation (depreciation) in amounts held for others	•	10,960,047	(794,408)
		• •	. , ,

See accompanying notes to consolidated financial statements.

Notes to Consolidated Financial Statements

June 30, 2024

(With comparative financial information as of and for the year ended June 30, 2023)

(1) Discussion of Operations and Summary of Significant Accounting Policies

The Rockefeller University (the University) is a world-renowned center for research and graduate education in the biomedical sciences, chemistry, bioinformatics, and physics. The University's 71 laboratories conduct both clinical and basic research and study a diverse range of biological and biomedical problems with the mission of improving the understanding of life for the benefit of humanity. Laboratories are loosely clustered in nine research areas covering a wide spectrum of disciplines in the life sciences, including neuroscience, immunology, genetics, structural biology, and bioinformatics. The University does not charge tuition. Its revenues are derived primarily from investment income, government grants and contracts, and private gifts and grants.

CLSI Incubator, LLC

CLSI Incubator, LLC (the Incubator) is a limited liability company. The University and the Incubator entered into the Limited Liability Company Agreement of Incubator, effective as of October 20, 2023. The Incubator, which is wholly owned by the University, is disregarded as a separate taxpayer from the University for federal income tax purposes and is organized and operated to support the exempt purposes of the University, including by promoting innovation by licensing space in premises owned by the University and leased to Incubator to early stage companies and organizations engaged in education and scientific innovation. The accompanying consolidated financial statements include the accounts of the University and its wholly owned subsidiary. All significant intercompany accounts have been eliminated in consolidation.

The significant accounting policies followed by the University are described below:

(a) Basis of Presentation

The University maintains its accounts in accordance with the principles of fund accounting. Under this method of accounting, resources for various purposes are classified into funds that are in accordance with activities or objectives specified by donors. Separate accounts are maintained for each fund.

For financial reporting purposes, however, the University prepares its consolidated financial statements on the accrual basis of accounting in accordance with standards established by the Financial Accounting Standards Board (FASB) or external reporting by not-for-profit organizations. Those standards require the classification of net assets and changes therein in two classes of net assets as follows:

- Without Donor Restrictions Net assets are not subject to donor-imposed restrictions but may be
 designated for specific purposes by the University or may be limited by contractual agreements
 with outside parties. In addition, changes in this category of net assets include returns on "funds
 functioning as endowment" and certain types of philanthropic support.
 - Such philanthropic support includes gifts without restrictions, including those designated by the Board of Trustees (the Board) to function as endowment and previously restricted gifts and grants for buildings that have been placed in service.
- With Donor Restrictions Net assets subject to donor-imposed restrictions that will be met either
 by actions of the University or the passage of time. Items that affect this net asset category are gifts

Notes to Consolidated Financial Statements

June 30, 2024

(With comparative financial information as of and for the year ended June 30, 2023)

with donor restrictions, including gifts for buildings not yet placed in service and unexpended investment returns on donor-imposed endowment funds that have not been appropriated for expenditure. Expirations of restrictions on net assets with donor restrictions, including reclassification of restricted gifts for buildings when the associated long-lived assets is placed in service, are reported as net assets restricted from restrictions.

Also included in the category are net assets subject to donor-imposed restrictions to be maintained permanently by the University, including gifts and pledges wherein donors stipulate that the corpus of the gift be held in perpetuity.

Revenue is reported as increases in net assets without donor restrictions unless limited by donor-imposed restrictions. Expenses are reported as decreases in net assets without donor restrictions. As discussed further in note 4, the University follows the provisions of Accounting Standards Codification (ASC) Topic 958, Subtopic 205-45, Classification of Donor-Restricted Endowment Funds Subject to the Uniform Prudent Management of Institutional Funds Act, which impacts the reporting of investment return on endowment funds. Accordingly, dividends, interest, and net gains and losses on endowment funds are reported as increases or decreases in net assets with donor restrictions until appropriated for expenditure by the University. Other changes within the consolidated statements of activities include postretirement-related changes other than net periodic postretirement benefit cost and nonroutine, nonoperating expenses.

(b) Fair Value Measurements

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. It prioritizes the inputs to the valuation techniques used to measure fair value by giving the highest priority to unadjusted quoted or published prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to measurements involving significant unobservable inputs (Level 3 measurements).

The three levels of the fair value hierarchy are as follows:

Level 1 inputs are quoted prices or published net asset values similar to those of a mutual fund (unadjusted) in active markets for identical assets or liabilities that the University has the ability to access at the measurement date.

Level 2 inputs are inputs other than quoted or published prices included in Level 1 that are either directly or indirectly observable for the assets or liabilities.

Level 3 inputs are unobservable inputs for the assets or liabilities.

The level in the fair value hierarchy within which a fair value measurement in its entirety falls is based on the lowest-level input that is significant to the fair value measurement in its entirety.

7

Notes to Consolidated Financial Statements

June 30, 2024

(With comparative financial information as of and for the year ended June 30, 2023)

(c) Cash Equivalents

All highly liquid debt instruments with an original maturity of three months or less are considered to be cash equivalents, except for such assets that are part of the University's investment portfolio managed by external investment managers for long-term purposes.

The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the consolidated balance sheet that sum to the total of the same such amounts shown in the consolidated statement of cash flows.

	-	2024	2023
Cash and cash equivalents Cash in investments	\$	66,956,928 22,951,297	31,142,442 45,230,280
Total cash, cash equivalents, and restricted cash shown in the statement of cash flows	\$	89,908,225	76,372,722

Cash included in investments is held with investment managers for liquidity and long-term investment purposes.

(d) Contributions

Contributions, including unconditional promises to give, are reported as revenues in the period received. Contributions to be received after one year are discounted to reflect the present value of future cash flows at a risk-adjusted rate. Amortization of the discount is recorded as additional contribution revenue in accordance with the donor-imposed restrictions, if any, on the contributions.

Contributions of property, plant, and equipment without donor stipulation concerning the use of such long-lived assets are reported as revenues of the net assets without donor restrictions class. Contributions of cash or other assets to be used to acquire property, plant, and equipment are reported as revenues of the net assets with donor restrictions class; the restrictions are considered to be released at the time such long-lived assets are placed into service. A contribution is conditional if the agreement includes both a barrier that must be overcome for the recipient to be entitled to the assets transferred and a right of return for the transferred assets or a right of release of the promisor's obligation to transfer assets. Conditional promises to give are recognized only when the barriers on which they depend are met and the promises become unconditional. Conditional contributions at June 30, 2024 and 2023 were approximately \$113,925,000 and \$88,189,000, respectively.

(e) Investments

Investments in equity securities with readily determinable fair values and all investments in debt securities are reported at fair value based upon quoted or published market values. Investments in partnerships, as a practical expedient, are reflected at net asset value (NAV) as reported by the general partners, and may differ from the values that would have been reported had a ready market for these securities existed. The University reviews and evaluates the values provided by the general

8

Notes to Consolidated Financial Statements

June 30, 2024

(With comparative financial information as of and for the year ended June 30, 2023)

partners and agrees with the valuation methods and assumptions used in determining the fair value of the limited partnerships.

(f) Plant Assets

Plant assets are stated at cost or at fair value at date of donation in the case of gifts. Depreciation of buildings and building improvements is recorded over estimated useful lives ranging from 15 to 50 years. Equipment is depreciated over estimated useful lives ranging from 5 to 10 years. Leasehold improvements are amortized over the life of the asset or term of the lease, whichever is shorter. Library books are depreciated over estimated useful lives of 15 years.

(g) Government Grants and Contracts

Revenue from government grants and contracts is generally recognized as earned, that is, as the related costs are incurred under the grant or contract agreements. Amounts expended in excess of reimbursements are reported as accounts receivable.

(h) Deferred Revenue

Deferred revenue primarily consists of amounts received from donors that do not meet the definition of a contribution as defined by ASC Topic 958-605. Such amounts are recognized as revenue to the extent of expenditure.

Notes to Consolidated Financial Statements

June 30, 2024

(With comparative financial information as of and for the year ended June 30, 2023)

(i) Revenue Recognition

In accordance with ASC Topic 606, the University accounts for a customer contract when both parties have approved the contract and are committed to perform their respective obligations, each party's rights can be identified, payment terms can be identified, the contract has commercial substance, and it is probable the University will collect substantially all of the consideration to which it is entitled.

Products and services	Nature, timing of satisfaction of performance obligations, and significant payment terms
Auxiliary enterprises	Consists of the following: *Press operations - Issues four different scientific journals. Subscription sales revenue is recognized on a straight-line basis over the subscription (contract) period (one year) up front.
	Housing services – Provides a variety of housing accommodations in support of the scientific needs of the University. Tenant's leases are for a one-year term. Revenue is recognized on a point in time basis.
	Food services – Provides food services to the University community through a cafeteria, café, and conference dining. Food service revenue is recognized at a point in time sale.
Royalty income	Royalty income is generated from licensing agreements the University enters with a third-party patentable inventions, tangible materials, and copyrighted materials are transferred to the for-profit sector for further development into useful commercial products and services. Licensing agreements can terminate for convenience. Agreements are milestone-based and revenue is recognized upon receipt (point in time) once certain milestones are achieved.

(j) Derivative Instruments

The University accounts for derivative instruments at fair value. The fair value of the derivatives held is based upon values provided by third-party financial institutions and is assessed by management for reasonableness. The fair values of the University's interest rate swaps were calculated as of June 30, 2024 using industry-recognized methodologies. The valuations are based on the present value of the difference between the fixed rate paid by the University and the midmarket fixed rate the University would pay on a similar transaction if it were entered into on June 30, 2024.

(k) Conditional Asset Retirement Obligation

Upon acquisition, and when reasonably estimable, the University recognizes the fair value of the liability related to the legal obligation to perform asset retirement activity on tangible long-lived assets.

Notes to Consolidated Financial Statements

June 30, 2024

(With comparative financial information as of and for the year ended June 30, 2023)

Over time, the liability is accreted to its settlement value. Upon settlement of the liability, the University will recognize a gain or loss for any difference between the settlement amount and liability recorded.

(I) Income Taxes

The University is exempt from federal income taxes under the provisions of Section 501(c)(3) of the Internal Revenue Code. The University follows the guidance of ASC Subtopic 740-10, *Income Taxes – Overall*, which addresses accounting for uncertainties in income taxes recognized in an enterprise's consolidated financial statements. The University utilizes a threshold of more-likely than-not for recognition and derecognition of tax positions taken or expected to be taken in a tax return. The University evaluates on an annual basis, the effect of any uncertain tax position on its consolidated financial statements. As of June 30, 2024, the University has not identified or provided for any such positions.

(m) Use of Estimates

The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingencies at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates made in the preparation of these consolidated financial statements include the valuation of investments, estimated net realizable value of receivables, the obligation under derivative instruments, and the postretirement benefit obligation. Actual results could differ from those estimates.

(n) Comparative Financial Information

The consolidated statement of activities is presented with prior year financial information in total, which does not include net asset class detail. Such information does not include sufficient detail to constitute a presentation in conformity with U.S. generally accepted accounting principles. Accordingly, such information should be read in conjunction with the University's 2023 consolidated financial statements, from which the summarized information was derived.

(o) Recently Adopted Accounting Pronouncements

In June 2016, the FASB issued Accounting Standards Update No. 2016-13, *Financial Instruments* – *Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments* (ASU), which requires a financial asset (or a group of financial assets) measured at amortized cost basis to be presented at the net amount expected to be collected. The ASU is intended to improve financial reporting by requiring earlier recognition of credit losses on certain financial assets. The measurement of expected credit losses is based on relevant information about past events, including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. The University adopted the provisions of the ASU in fiscal year 2024. The University adopted the provisions of the ASU using a prospective transition approach. As such, the University is not required to adjust comparative periods or provide comparative period disclosures. The adoption did not have a material impact on the University's consolidated financial statements at June 30, 2024.

Notes to Consolidated Financial Statements

June 30, 2024

(With comparative financial information as of and for the year ended June 30, 2023)

(p) Reclassifications

Certain amounts in the 2023 consolidated financial statements have been reclassified to conform to the 2024 presentation.

(2) Liquidity and Availability of Financial Assets

As of June 30, 2024 and 2023, financial assets and liquidity resources available within one year of the consolidated balance sheet date for general expenditure, such as operating expenses, scheduled debt service payments, and capital construction costs not financed with debt, were as follows:

	_	2024	2023
Financial assets:			
Cash and cash equivalents	\$	66,956,928	31,142,442
Accounts receivable		19,259,218	14,356,721
Contribution receivable due in one year, excluding endowment		60,625,879	58,089,313
Endowment spending in subsequent year	-	154,662,612	135,878,237
Total financial assets available within one year		301,504,637	239,466,713
Liquidity resources:			
Quasi-endowment funds without donor restrictions subject			
to board resolutions		266,172,344	262,228,220
Revolving credit agreement		100,000,000	100,000,000
Revolving credit agreement (expires January 2025)		15,000,000	25,000,000
Revolving credit agreement		_	100,000,000
Revolving credit agreement	-	50,000,000	50,000,000
Total financial assets available within one year and			
liquidity resources	\$	732,676,981	776,694,933

The University manages its financial assets to be available as its operating expenditures, liabilities, and other obligations come due. In addition, the University invests cash in excess of daily requirements in short-term investments or fixed-income securities. To manage additional liquidity, the University maintains lines of credit with several banks that are drawn upon as needed during the year to manage cash flows primarily for general corporate purposes. Amounts from the board-designated quasi-endowment funds could be made available if necessary through a board resolution.

Notes to Consolidated Financial Statements

June 30, 2024
(With comparative financial information as of and for the year ended June 30, 2023)

(3) Investments and Fair Value

The University's investments consist of the following at June 30, 2024 and 2023:

	_	2024	2023
Investments reported at fair value:			
Cash and cash equivalents (Level 1)	\$	88,741,293	64,180,814
U.S. long equities (Level 1)		9,557,508	8,540,710
International/ global equities (Level 1)		24,921,882	5,842,891
Other equities (Level 1)		34,971,487	28,969,097
Natural resources and other (Level 3)	_	3,187,500	
		161,379,670	107,533,512
Investments reported at net asset value:			
Public:			
U.S. long equities		216,417,901	204,895,833
International/global equities		170,599,084	202,382,936
Long/short equities		343,204,787	333,532,013
Absolute return	_	450,867,836	442,051,166
Total public at net asset value	_1	1,181,089,608	1,182,861,948
Private:			
Buyout funds		413,332,854	375,980,032
Venture capital funds		518,962,804	557,317,726
Real estate funds		76,468,186	97,582,576
Natural resources and other	_	230,597,055	204,666,783
Total private at net asset value	_1	1,239,360,899	1,235,547,117
Total investments	\$ _2	2,581,830,177	2,525,942,577

Investments include limited partnerships totaling approximately \$2.420 billion and \$2.415 billion at June 30, 2024 and 2023, respectively, which are presented above by the underlying investment classification.

Alternative investments – Public investments include interests in limited partnerships that invest principally in public equities and corporate bonds and may employ both long and short strategies.

Alternative investments – Private investments include interests in limited partnerships that invest principally in buyout funds, venture capital, real estate funds, and natural resources. These interests generally have very limited liquidity.

Notes to Consolidated Financial Statements

June 30, 2024

(With comparative financial information as of and for the year ended June 30, 2023)

A description of the various categories follows:

Long/short equities represent investments in funds that invest predominantly in liquid publicly traded marketable securities, primarily equities. These funds are able to hold both long and short positions and utilize leverage. These funds attempt to generate higher returns with lower volatility than their long-only counterparts and demonstrate moderate equity market correlation.

Absolute return represents investments in funds that pursue strategies that do not demonstrate a sustained correlation to public equity markets, such as distressed debt and credit strategies, market neutral strategies, macro strategies, event driven and merger arbitrage strategies, and deep value investing.

Buyout funds represent investments in funds that take negotiated, frequently controlling ownership stakes in companies in the United States and internationally.

Venture capital funds represent investments in companies that are newly formed and which require substantial initial capital.

Real estate funds represent investments in a broad range of commercial and residential real estate properties.

Natural resources and other represent investments in partnerships that invest in a broad range of natural resources, including oil and gas, timber, metals and mining, and power. The other category generally represents private partnerships in credit, royalty, or other nonequity investments.

At June 30, 2024, the University had approximately \$466.7 million for which capital calls had not been exercised pertaining to alternative investments – private. Such commitments generally have fixed expiration dates or other termination clauses. The University maintains sufficient liquidity to cover such calls. Investment securities are exposed to various risks, such as interest rate, market, and credit risks. Due to the level of risk associated with certain investment securities, it is at least reasonably possible that changes in the values of investment securities will occur in the near term and that such changes could materially affect the amounts reported in the consolidated balance sheet.

Notes to Consolidated Financial Statements

June 30, 2024

(With comparative financial information as of and for the year ended June 30, 2023)

Equities and alternative investments – public contain various monthly, quarterly, semiannual, and annual redemption restrictions with required written notice ranging up to 180 days. In addition, certain of these investments are restricted by initial lockup periods.

As of June 30, 2024, the following table summarizes at fair value the composition of various redemption provisions and lockup periods in the investment portfolio:

Redemption period		Long equities	Long/short equities	Absolute return	Total
Monthly	\$	_	129,875,315	26,806,304	156,681,619
Quarterly		182,713,125	85,790,037	299,444,496	567,947,658
Annual		55,476,758	_	_	55,476,758
In liquidation		1,840,694	3,994,420	80,972,484	86,807,598
Lockup (a)	_	146,986,408	123,545,015	43,644,552	314,175,975
Total	\$_	387,016,985	343,204,787	450,867,836	1,181,089,608

(a) The amount subject to redemption lockup is set to expire as follows:

	_	Amount	
Fiscal year:			
2025	\$	125,020,021	
2026		109,273,469	
Thereafter	_	79,882,485	
	\$_	314,175,975	

Notes to Consolidated Financial Statements

June 30, 2024

(With comparative financial information as of and for the year ended June 30, 2023)

As of June 30, 2023, the following table summarizes at fair value the composition of various redemption provisions and lockup periods in the investment portfolio:

			Public investm at net as	•	
Redemption period	<u> </u>	Long equities	Long/short equities	Absolute return	Total
Monthly	\$	_	105,248,416	51,220,681	156,469,097
Quarterly		147,377,215	90,232,351	131,994,666	369,604,232
Semiannual		13,589,000	_	118,938,700	132,527,700
Annual		46,661,548	_	27,431,849	74,093,397
In liquidation		31,301,816	24,521,565	41,894,309	97,717,690
Lockup (a)	_	146,597,801	113,529,681	70,570,961	330,698,443
Total	\$_	385,527,380	333,532,013	442,051,166	1,161,110,559

(a) The amount subject to redemption lockup is set to expire as follows:

	_	Amount	
Fiscal year:			
2024	\$	223,468,489	
2025		102,223,021	
Thereafter	_	5,006,933	
	\$_	330,698,443	

Private partnerships are invested through drawdown vehicles such that capital is drawn and repaid over time. On average, private partnerships have a cash flow weighted duration that ranges from three to five years.

Investment income, net consists of the following as of June 30:

		2024		
	Without donor	With donor		2023
	restrictions	restrictions	Total	Total
Interest and dividends, net Net appreciation	\$ 1,577,044	(3,348,732)	(1,771,688)	(2,051,015)
in fair value of investments	24,334,644	151,338,720	175,673,364	4,387,014
Total	\$ 25,911,688	147,989,988	173,901,676	2,335,999

Notes to Consolidated Financial Statements

June 30, 2024

(With comparative financial information as of and for the year ended June 30, 2023)

(4) Endowment Funds

The primary role of the endowment is to advance the research mission of the University through support of the annual operating budget. The University's endowment consists of both donor-restricted endowment funds and funds designated by the University for long-term purposes and is subject to the provision of the New York Prudent Management of Institutional Funds Act (NYPMIFA). The University has interpreted NYPMIFA as allowing it to appropriate for expenditure or accumulate so much of a donor-restricted endowment fund as is prudent for the uses, benefits, purposes, and duration for which the endowment fund is established, subject to the intent of the donor as expressed in the gift instrument absent explicit donor stipulations to the contrary.

The endowment's assets are invested in marketable securities, including U.S. and global equities and fixed income securities, and partnerships, including long/short equities, absolute return, venture capital, buyout funds, real estate funds, and natural resources. The assets are primarily invested by external investment managers through separate accounts or through commingled vehicles, including funds, trusts, and limited partnerships.

The Investment Committee of the University's Board of Trustees (the Committee) is responsible for overseeing the endowment. With the support of the Office of Investments, the Committee establishes the endowment's investment policy and asset allocation, retains and oversees external investment managers, and monitors the implementation and performance of the investment program. The Committee has established a long-term asset allocation policy, which is designed to earn superior investment returns while reducing the risk of permanent impairment of capital. The policy emphasizes (1) a substantial allocation to equity investments; (2) broad diversification of asset class, style, and manager; (3) low correlation to traditional equity market indices; (4) low volatility strategies; and (5) less efficient asset classes. The asset allocation policy is reviewed annually by the Committee. Actual asset allocation is reviewed quarterly by the Committee, which may tactically overweight or underweight a particular asset class.

(a) Spending Policy

The University operates under a modified inflation-based spending formula for operations. This formula consists of 70% of the allowable spending in the prior fiscal year, increased by the rate of inflation (Higher Education Price Index (HEPI)) and 30% of the current year spend rate applied to a 12-quarter average market value. The applied spending rate was 5.5% as of June 30, 2024 and 2023, respectively. The spending rate appropriation from the portion of the endowment without donor restrictions for the years ended June 30, 2024 and 2023 was \$98,184,329 and \$91,216,841, respectively.

(b) Funds with Deficiencies

From time to time, the fair value of endowment assets may fall below the fund's original value. Deficiencies of this nature are reported in net assets with donor restrictions. Underwater endowments were \$1,770,712 and \$2,250,640 as of June 30, 2024 and 2023, respectively. As of June 30, 2024, the historical gift value of the 12 underwater endowments was \$29,948,649 and the fair market value was \$28,177,937. As of June 30, 2023, the historical gift value of the 12 underwater endowments was \$26,364,210 and the fair market value was \$24,113,570.

Notes to Consolidated Financial Statements

June 30, 2024

(With comparative financial information as of and for the year ended June 30, 2023)

The University applies the aforementioned spending policy to its endowment accounts with deficiencies by utilizing the accumulated gains on the board-designated endowment without donor restrictions.

At June 30, 2024 and 2023, net assets associated with endowment funds, exclusive of pledges and nonpooled endowments principally in trusts, consisted of the following:

		2024	
	Without donor restrictions	With donor restrictions	Total
Donor restricted Designated for long-term purposes	\$ 266,172,344	2,153,928,602 ——	2,153,928,602 266,172,344
Total	\$ 266,172,344	2,153,928,602	2,420,100,946
		2023	
	Without donor restrictions	With donor restrictions	Total
Donor restricted Designated for long-term purposes	\$ 262,228,220	2,103,191,261 —	2,103,191,261 262,228,220
Total	\$ 262.228.220	2,103,191,261	2.365.419.481

Changes in net assets associated with endowment funds, exclusive of pledges and nonpooled endowments principally in trusts, for the years ended June 30, 2024 and 2023, were as follows:

		2024	
	Without donor restrictions	With donor restrictions	Total
Net assets at June 30, 2023 Contributions	\$ 262,228,220	2,103,191,261 14.273,279	2,365,419,481 14,273,279
Investment gain, net Transfers, net	31,177,963 7,150,000	147,989,988 (5,226,346)_	179,167,951 1,923,654
Total before spending rate	300,556,183	2,260,228,182	2,560,784,365
Endowment spending rate: Without donor restrictions With donor restrictions	(34,383,839)	(98,184,329) (8,115,251)	(132,568,168) (8,115,251)
Total endowment spending rate	(34,383,839)	(106,299,580)	(140,683,419)
Net assets at June 30, 2024	\$ 266,172,344	2,153,928,602	2,420,100,946

Notes to Consolidated Financial Statements

June 30, 2024
(With comparative financial information as of and for the year ended June 30, 2023)

		2023	
	Without donor restrictions	With donor restrictions	Total
Net assets at June 30, 2022 Contributions	\$ 415,974,863	2,192,241,394	2,608,216,257
Investment gain (loss), net	3,865,433	28,194,902 (13,680,707)	28,194,902 (9,815,274)
Transfers, net	9,150,000	(6,375,851)	2,774,149
Total before spending rate	428,990,296	2,200,379,738	2,629,370,034
Endowment spending rate: Without donor restrictions With donor restrictions	(26,762,076)	(91,216,841) (5,971,636)	(117,978,917) (5,971,636)
Total endowment spending rate	(26,762,076)	(97,188,477)	(123,950,553)
Total before draw for operations	402,228,220	2,103,191,261	2,505,419,481
Draw for operations	(140,000,000)		(140,000,000)
Net assets at June 30, 2023	\$ 262,228,220	2,103,191,261	2,365,419,481

During fiscal year 2023, the University withdrew \$140,000,000 from the endowment primarily to temporarily fund settlements, legal fees, and other expenses (see note 12). The University plans on repaying the endowment.

(5) Obligation under Lines of Credit

On November 1, 2022, the University entered into a revolving credit agreement with a financial institution. This agreement consists of a \$100 million committed facility, expiring on November 1, 2025, to be used for general institutional purposes. The facility borrowings may occur at the Secured Overnight Financing Rate (SOFR) + 0.10% plus 0.50%. The commitment fee on the facility is 0.45% of the undrawn balance. There was \$0 outstanding as of June 30, 2024 and 2023, respectively.

On January 4, 2024, the University entered into a revolving credit agreement with a financial institution. This agreement consists of a \$15 million committed facility, expiring on January 4, 2025, to be used for general institutional purposes. The previous agreement, which expired on January 4, 2024, consisted of a \$25 million committed facility. The facility borrowings may occur at the SOFR plus 0.55%. The commitment fee on the facility is 0.10% of the undrawn balance. There was \$0 outstanding as of June 30, 2024 and 2023, respectively.

On May 4, 2022, the University entered into a revolving credit agreement with a financial institution. The agreement consists of a \$100 million committed facility, expiring on May 3, 2027, to be used for general institutional purposes. The facility borrowings may occur at the SOFR plus 0.43%. The commitment fee on the facility is 0.10% of the undrawn balance. There was \$100,000,000 outstanding as of June 30, 2024 and \$0 as of June 20, 2023.

Notes to Consolidated Financial Statements

June 30, 2024

(With comparative financial information as of and for the year ended June 30, 2023)

On March 23, 2023, the University entered into a revolving credit agreement with a financial institution. The agreement will consist of a three-year \$50 million committed facility to be used for general corporate purposes. The facility borrowings may occur at the Bloomberg Short-Term Bank Yield (BSBY) plus 1.35%. The commitment fee on the facility will be 0.20% of the undrawn balance. There was \$0 outstanding as of June 30, 2024 and 2023, respectively.

Fees relating to the obligation under the lines of credit for the years ended June 30, 2024 and 2023 were approximately \$696,000 and \$420,000, respectively. Interest expense on the lines of credit was \$3,747,000 and \$4,590,000 as of June 30, 2024 and 2023, respectively.

Notes to Consolidated Financial Statements

June 30, 2024
(With comparative financial information as of and for the year ended June 30, 2023)

(6) Long-Term Debt

The University has financed certain plant asset acquisition and construction costs, and obtained general institutional liquidity, through revenue obligations of the Dormitory Authority of the State of New York (the Authority) and other sources.

The following obligations were outstanding at June 30, 2024 and 2023:

	_	2024	2023
The Rockefeller University Revenue Bonds, Series 2022A, 4% to 5%, due serially to 2042	\$	70,400,000	70,400,000
Note payable, direct placement 1.25%, due serially 2026		100,000,000	100,000,000
The Rockefeller University Revenue Bonds, Series 2020A, 5.00%, due serially to 2053		40,985,000	40,985,000
The Rockefeller University Revenue Bonds, Series 2020B, 3.75%, due 2051		75,345,000	75,345,000
The Rockefeller University Revenue Bonds, Series 2019A, 5.00%, due 2035		46,770,000	46,770,000
The Rockefeller University Revenue Bonds, Series 2019B, 5.00%, due 2050		73,285,000	73,285,000
The Rockefeller University Revenue Bonds, Series 2019C, 4.00%, due 2049		89,365,000	89,365,000
The Rockefeller University Revenue Bonds, Series 2017A, variable rate, partially			
hedged by interest rate swap, due 2052 (effective rate 2.66% and 2.81% as of			
June 30, 2024 and 2023, respectively)		100,445,000	100,445,000
Note payable, direct placement 3.77%, due serially to 2045		25,000,000	25,000,000
The Rockefeller University Revenue Bonds, Series 2015A, variable rate, partially			
hedged by interest rate swap, due 2045 (effective rate 4.14% and 4.24% as of			
June 30, 2024 and 2023, respectively)		119,190,000	119,190,000
The Rockefeller University Revenue Bonds, Series 2015B, variable rate, partially			
hedged by interest rate swap, due 2045 (effective rate 4.01% and 3.92% as			
of June 30, 2024 and 2023, respectively)		44,000,000	44,000,000
The Rockefeller University Revenue Bonds, Series 2008A, variable rate, partially			
hedged by interest rate swap, due 2039 (effective rate 5.28% and 5.51% as			
of June 30, 2024 and 2023, respectively)		103,215,000	103,215,000
The Rockefeller University Revenue Bonds, Series 2002A2, variable rate, partially			
hedged by interest rate swap, due 2032 (effective rate 4.46% and 4.89%			
as of June 30, 2024 and 2023, respectively)	-	50,000,000	50,000,000
		938,000,000	938,000,000
Unamortized bond premium	\$	49,491,077	52,074,817
Unamortized bond issuance costs	*	(3,814,742)	(4,060,002)
	\$	983,676,335	986,014,815
	Ψ.	000,070,000	500,017,010

The Series 2012A, 2012B, 2019A, 2019B, 2019C, 2020A, and the 2022A bonds were issued at a premium, which are being amortized over the lives of the bonds.

Notes to Consolidated Financial Statements

June 30, 2024

(With comparative financial information as of and for the year ended June 30, 2023)

As of June 30, 2024, the University's projected debt service payments on its long-term debt are as follows:

	Principal	Interest	Total debt service
Year ending June 30:			
2025	\$ -	37,315,592	37,315,592
2026	100,000,000	36,863,537	136,863,537
2027	_	36,065,592	36,065,592
2028	_	36,065,592	36,065,592
2029	2,000,000	36,065,592	38,065,592
Thereafter	836,000,000	576,089,290	1,412,089,290
	\$ 938,000,000	758,465,195	1,696,465,195

Interest expense on long-term debt for the years ended June 30, 2024 and 2023 was approximately \$37,812,000 and \$37,271,000, respectively.

In April 2022, the University entered into a bond refinancing transaction. The Series 2022A bonds refunded the 2012A and the 2012B bonds and bears interest at a fixed rate. The refunding of the 2012A and 2012B bonds resulted in a gain of approximately \$3,231,0003.

In February 2021, the University entered into a note purchase agreement with a major insurance company for \$100,000,000, with principal due February 18, 2026.

In May 2020, the University entered into two bond transactions. The Series 2020A bonds refunded the Series 2010A bonds and bear interest at a fixed rate. The Series 2020B bonds bear interest at a fixed rate and were issued for general institutional liquidity.

In December 2019, the University entered into two bond transactions. The 2019A bonds refunded the 2009A bonds and bear interest at a fixed rate. The 2019B and 2019C bonds were issued jointly and bear interest at a fixed rate. The 2019B bonds issued for additional financing for a construction project. The 2019C bonds refunded the 2009C bonds.

On April 10, 2015, the University entered into a note purchase agreement with a major insurance company for \$25 million, with principal due April 10, 2045.

The Series 2015A bonds bear interest at a variable rate and were directly placed with a financial institution for an initial 10-year period through a bond purchase and placement agreement. The 2015B bonds bear interest at a variable rate and were directly placed with a financial institution through a bond purchase and placement agreement.

The Series 2002A2 bonds and the Series 2008A bonds bear interest at variable rates and are subject to optional and mandatory tender. The University has entered into agreements with remarketing agents

Notes to Consolidated Financial Statements

June 30, 2024

(With comparative financial information as of and for the year ended June 30, 2023)

pursuant to which the remarketing agents are obligated to use their best efforts to remarket any bonds so tendered. The University is obligated to purchase any bonds that are tendered but not remarketed. In connection with the Series 2002A2 and 2008A bonds, the University arranged for a standby purchase agreement to be provided by a bank, pursuant to which the bank will purchase any bonds that are tendered and not remarketed.

On August 3, 2017, the Series 2009B bonds were refunded through proceeds from the 2017A bonds. The 2017A bonds were issued in the amount of \$100,445,000. The 2017A bonds bear interest at a variable rate and were directly placed with a financial institution for an initial 10-year period through a bond purchase and placement agreement.

On June 1, 2022, the University changed from the London Interbank Offered Rate (LIBOR) to the Secured Overnight Financing Rate (SOFR) for interest on its variable rate bond issues, 2002A2, 2008A, 2015A, 2015B, and 2017A.

Interest Rate Swap Agreements

The University has entered into five interest rate swap agreements. The following schedule presents the notional principal amounts of the swaps and other related information as of June 30, 2024:

Effective date	 Notional amount	Termination date
January 31, 2002	\$ 50,000,000	2032
May 2, 2005	50,000,000	2032
July 1, 2008	100,000,000	2039
July 1, 2009	100,000,000	2040
July 1, 2010	75,000,000	2040

The swaps are a partial hedge of the Series 2002A2, 2008A, 2015A, 2015B, and 2017A bond issues. Under the terms of the agreements, the University pays interest at predetermined fixed rates and receives variable rates. Included in obligation under derivative instruments in the consolidated balance sheet is the net cumulative loss on these derivative transactions in the amounts of \$51,397,387 and \$67,473,916 (Level 2 in the fair value hierarchy) at June 30, 2024 and 2023, respectively. Additionally, the change in the cumulative loss is included in net appreciation in fair value of derivative instruments in the accompanying consolidated statement of activities and amounted to \$16,076,529 and \$27,374,167 for the years ended June 30, 2024 and 2023, respectively.

In June 2023, the University converted the underlying interest rate on its swaps from LIBOR to SOFR under the International Swaps and Derivatives Association (ISDA) protocols.

Notes to Consolidated Financial Statements

June 30, 2024
(With comparative financial information as of and for the year ended June 30, 2023)

(7) Plant Assets

Plant assets at June 30, 2024 and 2023 comprise the following:

	_	2024	2023
Land and land improvements	\$	32,979,028	32,974,959
Buildings and building improvements		1,760,900,048	1,746,583,135
Equipment		129,315,261	128,595,808
Leasehold improvements		460,112	460,112
Library books		755,237	755,237
Works of art	_	890,664	890,664
Total		1,925,300,350	1,910,259,915
Less accumulated depreciation and amortization		(884,300,012)	(834,327,731)
Construction in progress	-	35,321,384	28,320,879
	\$	1,076,321,722	1,104,253,063

(8) Retirement Benefits

The University has defined-contribution retirement plans covering substantially all academic and nonacademic personnel. The plans are fully funded by the purchase of annuity contracts. Pension costs amounted to approximately \$12,824,000 and \$12,067,000 for the years ended June 30, 2024 and 2023, respectively.

In addition to providing pension benefits, the University provides certain healthcare and life insurance benefits for retired faculty and administrative employees who meet certain age and length-of-service requirements upon retirement. The University recognizes the funded status (i.e., the difference between the fair value of plan assets and projected benefit obligations) of its benefit plan as an asset or liability in its consolidated balance sheet and recognizes changes in that funded status in the year in which the changes occur through changes in net assets without donor restrictions.

Notes to Consolidated Financial Statements

June 30, 2024
(With comparative financial information as of and for the year ended June 30, 2023)

The following table sets forth the postretirement benefit plan's funded status and amounts recognized in the University's consolidated financial statements as of and for the years ended June 30, 2024 and 2023:

	_	2024	2023
Change in benefit obligation:			
Benefit obligation at beginning of year	\$	94,472,000	101,990,000
Service cost		2,708,000	3,160,000
Interest cost		4,864,000	4,765,000
Plan participants' contributions		783,000	642,000
Actuarial gain		4,784,000	(11,129,000)
Benefits paid	_	(5,267,000)	(4,956,000)
Benefit obligation at end of year	_	102,344,000	94,472,000
Change in plan assets:			
Fair value of plan assets at beginning of year		36,322,000	31,912,000
Actual return on plan assets		5,228,000	4,410,000
Employer contribution		4,484,000	4,314,000
Plan participants' contributions		783,000	642,000
Benefits paid	_	(5,267,000)	(4,956,000)
Fair value of plan assets at end of year (Level 1 inputs)	_	41,550,000	36,322,000
Accrued postretirement benefit obligation (APBO)	\$_	60,794,000	58,150,000

The components of net periodic postretirement benefit cost for the years ended June 30 are as follows:

	_	2024	2023
Service cost	\$	2,708,000	3,160,000
Interest cost		4,864,000	4,765,000
Expected return on plan assets		(2,503,000)	(2,199,000)
Amortization of net gain		(861,000)	
Net periodic postretirement benefit cost	\$_	4,208,000	5,726,000

The amount of actuarial gain amortized into net periodic postretirement benefit cost in 2025 is estimated to be \$(565,000).

As of June 30, 2024 and 2023, the postretirement benefit obligation includes net actuarial gains of \$17,721,000 and \$20,641,000, respectively.

Notes to Consolidated Financial Statements

June 30, 2024

(With comparative financial information as of and for the year ended June 30, 2023)

Weighted average assumptions used to calculate the benefits obligation and to determine net periodic pension cost as of and for the years ended June 30 are as follows:

	2024	2023
Discount rate for benefit obligation	5.670 %	5.270 %
Discount rate for net periodic postretirement cost	5.270	4.700
Expected return on plan assets	6.89	6.89

For measurement purposes, an annual increase in the per capita cost of covered healthcare and prescription drug benefits was assumed. As of June 30, 2024, the initial trend rates are assumed to be 6.25% for pre-65 medical claims, 5.75% for post-65 medical claims, 10.25% for both pre-65 and post-65 prescription drug claims, and 7.96% for Medicare Advantage claims. These rates are assumed to reach an ultimate rate of 4.00% in 2045 and remain at that level thereafter. The trend rates grade to a projected long-term annual growth of inflation, real GDP growth, NHE excess trend, and additional experience. Assumed healthcare cost trends have a significant effect on the amounts reported for the healthcare plans.

The asset allocation of the postretirement benefit plan as of June 30 was:

	2024	2024 Target	2023	2023 Target
Asset category:				
Equities	85 %	75 %	83 %	75 %
Fixed income	15	25	17	25
	100 %	100 %	100 %	100 %

The fair value of plan assets as of June 30, 2024 and 2023 includes equity mutual funds of approximately \$35.2 million and \$30.1 million, respectively, and fixed income mutual funds of approximately \$6.4 million and \$6.2 million, respectively. These instruments are considered level 1 investments in the fair value hierarchy.

The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 is reflected assuming that the University will continue to provide a prescription drug benefit to plan participants that is at least actuarially equivalent to Medicare Part D. The University received the federal subsidy until 2018. The amounts do not reflect the effects, if any, of the Patient Protection and Affordable Care Act and Health Care and Reconciliation Act that were enacted in March 2010.

Notes to Consolidated Financial Statements

June 30, 2024

(With comparative financial information as of and for the year ended June 30, 2023)

The benefits expected to be paid in each fiscal year from 2025 to 2029 and the five subsequent years thereafter are as follows:

	_	Payments not reflecting Medicare subsidy	Medicare subsidy	Benefits reflecting Medicare subsidy
2025	\$	4,533,000	222,000	4,311,000
2026		4,812,000	227,000	4,585,000
2027		5,067,000	234,000	4,833,000
2028		5,323,000	241,000	5,082,000
2029		5,617,000	245,000	5,372,000
2030–2034		32,194,000	1,322,000	30,872,000

The expected benefits to be paid are based on the same assumptions used to measure the University's benefit obligation at June 30, 2024.

Employer contributions of approximately \$4.3 million are expected to be made in 2025.

(9) Contributions Receivable

Contributions receivable consist of the following at June 30, 2024 and 2023:

	_	2024	2023
Amounts expected to be collected in:			
Less than one year	\$	70,440,020	66,455,593
One year to five years		127,303,628	124,574,200
Thereafter	_	28,632,000	39,630,000
		226,375,648	230,659,793
Less allowance		(2,500,000)	(2,500,000)
Less discount to present value at a 5% rate at June 30, 2024		, , ,	(, , , ,
and 2023	=	(19,105,947)	(21,643,329)
	\$_	204,769,701	206,516,464

Included in gross contributions receivable at June 30, 2024 and 2023 is approximately \$83 million and \$98 million, respectively, due from three donors.

Notes to Consolidated Financial Statements

June 30, 2024

(With comparative financial information as of and for the year ended June 30, 2023)

(10) Net Assets

Net assets consist of the following as of June 30, 2024 and 2023:

		20:	24		202		
	-	Without donor restrictions	With donor restrictions	2024 Total	Without donor restrictions	With donor restrictions	2023 Total
Operations	\$	(469,655,976)	_	(469,655,976)	(386,518,825)	_	(386,518,825)
Net investment in plant		267,990,387	_	267,990,387	293,583,247	_	293,583,247
Endowment funds without							
donor restrictions		266,172,344	_	266,172,344	262,228,220	_	262,228,220
Underwater endowment funds		_	(1,770,712)	(1,770,712)	_	(2,250,640)	(2,250,640)
Research		_	120,954,763	120,954,763	_	95,368,023	95,368,023
Research support		_	784,527	784,527	_	303,421	303,421
Graduation education		_	679,450	679,450	_	679,650	679,650
Renovation of facilities		_	510,384	510,384		2,167,299	2,167,299
Subsequent years:							
Pledges - Facilities		_	48,197,627	48,197,627	_	54,985,189	54,985,189
Pledges – Program		_	125,395,253	125,395,253	_	129,840,592	129,840,592
Pledges – Endowment		_	22.649.907	22,649,907	_	21,690,683	21,690,683
Accumulated gains		_	1.676.480.484	1,676,480,484	_	1,640,496,350	1,640,496,350
Annuity trust and split interest			,,, .	,,, .		,,,	, , , , , , , , , , , , , , , , , , , ,
agreements		_	296,491	296.491	_	296,491	296,491
Permanent endowment corpus		_	479,218,830	479,218,830	_	464,945,551	464,945,551
	-		,210,000	,210,000		,510,001	, 5 . 0 , 0 0 1
	\$	64,506,755	2,473,397,004	2,537,903,759	169,292,642	2,408,522,609	2,577,815,251

The endowment funds without donor restrictions consisted of the following at June 30, 2024 and 2023:

	_	2024	2023
Working capital in the endowment	\$	44,783,439	44,026,633
Other funds designated for long-term investment	_	221,388,905	218,201,587
	\$_	266,172,344	262,228,220

Net assets released from restrictions as of June 30, 2024 consisted of the following:

Spending on restricted funds:		
Research	\$	107,341,652
Facilities		10,686,156
Education		496,058
Endowment spending rate:		
Board appropriated spending		98,184,329
Restricted spending:		
Research		8,111,751
Education	_	3,500
Total	\$	224,823,446

Notes to Consolidated Financial Statements

June 30, 2024

(With comparative financial information as of and for the year ended June 30, 2023)

(11) Expenses by Natural Classification by Function

Expenses are reported in the consolidated statement of activities in categories recommended by the National Association of College and University Business Officers. The University's primary program services are research and graduate education. Expenses reported as research support and auxiliary enterprises are incurred in support of these primary program services. Accordingly, total program services expenses approximated \$413,400,000 and \$372,494,000 in 2024 and 2023, respectively. Institutional support includes approximately \$10,888,000 and \$10,182,000 of fundraising expenses in 2024 and 2023, respectively. Operations and maintenance of plant and depreciation are allocated to program and supporting activities based upon square footage. Interest is allocated to program and supporting activities based upon the usage of bond proceeds.

Expenses are reported in the consolidated statement of activities in functional categories. Natural expenses were categorized as follows:

					2024			
	Operations and							
	_	Research	Education	Research support	maintenance of plant (O&M)	Institutional support	Auxiliary enterprises	Total
Salaries and benefits	\$	109,640,098	2,567,826	37,265,694	19,912,741	36,599,182	8,702,729	214,688,270
Supplies and other		37,045,834	8,546,320	6,230,681	8,614,974	2,049,208	13,695,217	76,182,234
Fellowships and stipends		6,462,875	7,086,105	_	_	_	_	13,548,980
Subcontracts		16,928,460	_	_	_	_	_	16,928,460
Professional fees and service contracts		19,805,829	364,855	7,409,536	8,589,429	4,123,312	2,246,799	42,539,760
Depreciation and amortization		30,380,010	3,064,730	2,908,037	4,326,804	4,898,052	8,931,567	54,509,200
Interest and related costs		27,516,476	_	5,058,348	211,926	8,724,397	605,217	42,116,364
O&M – Utilities		36,228,265	187,866	9,828,896	(39,886,386)	2,923,740	4,866,026	14,148,407
Interdepartmental charges	_	21,292,530	(286,336)	(22,355,136)	(1,769,488)	1,943,620	1,174,810	
Total functional expenses		305,300,377	21,531,366	46,346,056	_	61,261,511	40,222,365	474,661,675
Postretirement-related changes other than service costs		(23,842)	(1,224)	(15,282)	_	(19,566)	(4,086)	(64,000)
Litigation payments	_					83,634,490		83,634,490
Total expenses and								
other changes	\$_	305,276,535	21,530,142	46,330,774		144,876,435	40,218,279	558,232,165

Notes to Consolidated Financial Statements

June 30, 2024
(With comparative financial information as of and for the year ended June 30, 2023)

					2023				
		Operations							
		and December 1997							
	_	Research	Education	Research support	maintenance of plant (O&M)	Institutional support	Auxiliary enterprises	Total	
Salaries and benefits	\$	97,439,105	2,473,057	33,937,690	18,414,137	33,725,199	8,237,585	194,226,773	
Supplies and other		31,418,268	6,825,948	9,293,872	9,028,592	3,700,835	12,658,515	72,926,030	
Fellow ships and stipends		5,693,082	6,614,001	_	_	_	_	12,307,083	
Subcontracts		16,999,838	_	_	_	_	_	16,999,838	
Professional fees and service contracts		10,601,833	375,851	7,840,654	7,627,287	4,001,525	1,583,344	32,030,494	
Depreciation and amortization		30,599,993	3,155,799	3,000,887	4,447,626	4,987,475	9,031,864	55,223,644	
Interest and related costs		27,265,917	_	4,877,130	209,689	9,454,847	605,519	42,413,102	
O&M – Utilities		33,775,106	174,532	9,160,458	(38,052,023)	2,724,869	4,396,485	12,179,427	
Interdepartmental charges	_	20,989,407	(435,336)	(21,936,436)	(1,675,308)	1,922,293	1,135,380		
Total functional expenses		274,782,549	19,183,852	46,174,255	_	60,517,043	37,648,692	438,306,391	
Postretirement-related changes other than service costs		(F F70 242)	(262,126)	(2.840.002)		(4.420.067)	(1.010.561)	(15 000 000)	
		(5,572,343)	(202, 120)	(3,810,903)	_	(4,430,067)	(1,012,561)	(15,088,000)	
Litigation payments	-					70,064,213		70,064,213	
Total expenses and									
other changes	\$_	269,210,206	18,921,726	42,363,352		126,151,189	36,636,131	493,282,604	

(12) Contingent Liabilities

Amounts expended by the University under various government grants and contracts are subject to audit by governmental agencies. In the opinion of management, audit adjustments, if any, will not have a significant effect on the University's financial position.

During 2018, the University retained external legal counsel to investigate a report by a former patient of inappropriate conduct by a former physician at the Rockefeller University Hospital. The University made publicly available the external counsel's report on its investigation. The University also established the Rockefeller Hospital Therapy Fund to provide financial assistance for therapy costs.

The NYS Child Victims Act (CVA), which was passed in February 2019, modified the statute of limitations for civil claims relating to certain childhood abuse claims and created a one-year window, which was subsequently extended for an additional year, from August 14, 2019, until mid-August 2021, during which persons could initiate civil lawsuits. On March 1, 2023, an amendment to the NYC Gender Motivated Violence Protection Act (GMVPA), which created a two-year window during which persons may bring civil lawsuits for gender-based crimes, became effective. For the year ended June 30, 2024, approximately \$83.6 million has been recorded in the consolidated financial statements for CVA and GMVPA settlements, legal fees, investigation costs, and other expenses through November ___, 2024. Future costs and other expenses relating to this matter cannot be reasonably estimated at this time. The University expects that a number of these claims will be covered by existing insurance coverage and has filed a lawsuit against its insurers to recover proceeds in connection with these claims.

The University is a defendant in various other lawsuits. Management of the University does not expect the ultimate resolution of these actions to have a significant effect on the University's financial position.

Notes to Consolidated Financial Statements

June 30, 2024

(With comparative financial information as of and for the year ended June 30, 2023)

(13) Affiliated Entities

The Rockefeller Archive Center

The Rockefeller Archive Center (RAC) was a division of the University. On June 20, 2006, RAC was formed as a separate legal entity with a board of trustees separate and distinct from the University's board of trustees. The University's president participates in RAC's board of trustees.

The University has entered into an agreement whereby it is providing investment services to RAC. Amounts held for others in the amount of \$151,594,988 and \$151,017,718 as of June 30, 2024 and 2023, respectively, represent the fair value (Level 3 in the fair value hierarchy) of RAC's units in the University's endowment pool. RAC, upon written notice to the University, may submit a request to redeem all or a portion of the units held by RAC. Each redemption request shall be no less than \$2 million. After receiving the redemption request, the University shall notify RAC of the portion, if any, of the redemption request that is accepted and the manner and timing of payment of the redemption amounts. The dispositions, which include redemptions and appropriations for spending, are \$10,198,407 and \$8,324,354 for the years ended June 30, 2024 and 2023, respectively, and total appreciation (depreciation) on the amounts are \$10,960,048 and \$(794,408) for the years ended June 30, 2024 and 2023, respectively. Pursuant to the terms of the investment services agreement, RAC has no beneficial interest or rights with respect to the University's underlying investments.

Tri-Institutional Therapeutics Discovery Institute

Tri-Institutional Therapeutics Discovery Institute (TDI) is a nonprofit corporation formed in 2013 to further and improve health and the diagnosis, prevention, and treatment of disease through furthering and improving translational research. TDI is controlled and governed by the University and two other leading not-for-profit academic, medical, and research institutions. The University's president and two additional University faculty members participate on TDI's board of directors. The University provides accounting and tax services to TDI on a pro bono basis.

The collaboration agreement among TDI and the Tri-Institutional members states that each Tri-Institutional member will provide pro rata funding annually (calendar year basis) determined by TDI's board of directors in support of TDI's activity. In 2024 and 2023, the University provided funding of \$2,000,000, respectively, to TDI.

(14) Subsequent Events

The University evaluated events subsequent to June 30, 2024 through November 13, 2024, the date on which the consolidated financial statements were issued and concluded that no additional disclosures are required, except as referred to above in note 12.